» Articles » PMID: 27178811

Thermostabilization of Inactivated Polio Vaccine in PLGA-based Microspheres for Pulsatile Release

Overview
Specialty Pharmacology
Date 2016 May 15
PMID 27178811
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccines are a critical clinical tool in preventing illness and death due to infectious diseases and are regularly administered to children and adults across the globe. In order to obtain full protection from many vaccines, an individual needs to receive multiple doses over the course of months. However, vaccine administration in developing countries is limited by the difficulty in consistently delivering a second or third dose, and some vaccines, including the inactivated polio vaccine (IPV), must be injected more than once for efficacy. In addition, IPV does not remain stable over time at elevated temperatures, such as those it would encounter over time in the body if it were to be injected as a single-administration vaccine. In this manuscript, we describe microspheres composed of poly(lactic-co-glycolic acid) (PLGA) that can encapsulate IPV along with stabilizing excipients and release immunogenic IPV over the course of several weeks. Additionally, pH-sensitive, cationic dopants such as Eudragit E polymer caused clinically relevant amounts of stable IPV release upon degradation of the PLGA matrix. Specifically, IPV was released in two separate bursts, mimicking the delivery of two boluses approximately one month apart. In one of our top formulations, 1.4, 1.1, and 1.2 doses of the IPV serotype 1, 2, and 3, respectively, were released within the first few days from 50mg of particles. During the delayed, second burst, 0.5, 0.8, and 0.6 doses of each serotype, respectively, were released; thus, 50mg of these particles released approximately two clinical doses spaced a month apart. Immunization of rats with the leading microsphere formulation showed more robust and long-lasting humoral immune response compared to a single bolus injection and was statistically non-inferior from two bolus injections spaced 1 month apart. By minimizing the number of administrations of a vaccine, such as IPV, this technology can serve as a tool to aid in the eradication of polio and other infectious diseases for the improvement of global health.

Citing Articles

GLP-1 Analogue-Loaded Glucose-Responsive Nanoparticles as Allies of Stem Cell Therapies for the Treatment of Type I Diabetes.

Marques J, Nunes R, Carvalho A, Florindo H, Ferreira D, Sarmento B ACS Pharmacol Transl Sci. 2024; 7(5):1650-1663.

PMID: 38751616 PMC: 11092009. DOI: 10.1021/acsptsci.4c00173.


Single administration vaccines: delivery challenges, in vivo performance, and translational considerations.

Michaelides K, Prasanna M, Badhan R, Mohammed A, Walters A, Howard M Expert Rev Vaccines. 2023; 22(1):579-595.

PMID: 37395004 PMC: 10332286. DOI: 10.1080/14760584.2023.2229431.


Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems.

Baryakova T, Pogostin B, Langer R, McHugh K Nat Rev Drug Discov. 2023; 22(5):387-409.

PMID: 36973491 PMC: 10041531. DOI: 10.1038/s41573-023-00670-0.


A Scalable Platform for Fabricating Biodegradable Microparticles with Pulsatile Drug Release.

Graf T, Qiu S, Varshney D, Laracuente M, Euliano E, Munnangi P Adv Mater. 2023; 35(22):e2300228.

PMID: 36862114 PMC: 10247432. DOI: 10.1002/adma.202300228.


Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.

Kumar P, Bird C, Holland D, Joshi S, Volkin D Hum Vaccin Immunother. 2022; 18(7):2154100.

PMID: 36576132 PMC: 9891683. DOI: 10.1080/21645515.2022.2154100.


References
1.
Cleland J . Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol. 1999; 17(1):25-9. DOI: 10.1016/s0167-7799(98)01272-4. View

2.
van de Weert M, Hennink W, Jiskoot W . Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2001; 17(10):1159-67. DOI: 10.1023/a:1026498209874. View

3.
Qi W, Zeng Y, Orgel S, Francon A, Kim J, Randolph T . Preformulation study of highly purified inactivated polio vaccine, serotype 3. J Pharm Sci. 2013; 103(1):140-51. DOI: 10.1002/jps.23801. View

4.
Kang S, Jeon O, Kim B . Poly(lactic-co-glycolic acid) microspheres as an injectable scaffold for cartilage tissue engineering. Tissue Eng. 2005; 11(3-4):438-47. DOI: 10.1089/ten.2005.11.438. View

5.
Kang J, Schwendeman S . Comparison of the effects of Mg(OH)2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants. Biomaterials. 2002; 23(1):239-45. DOI: 10.1016/s0142-9612(01)00101-6. View